Fundz

Microbot Medical

Hingham, Massachusetts, United States · Biotechnology, Healthcare, Health Care

Microbot Medical’s vision is to improve the quality of life of millions of patients globally by advancing robotic technologies to perform surgical procedures within the human body, and offer physicians and their patients less invasive and more precise solutions. The company’s innovations tap into one of the fastest-growing spaces in the medical field, the minimal invasive space. Microbot Medical d

Key facts

Headquarters
Hingham, Massachusetts, United States
Employees
37
Industries
Biotechnology, Healthcare, Health Care
Status
Public (MBOT)
Website
microbotmedical.com
LinkedIn
Company page

Recent activity at Microbot Medical

  • : Microbot Medical Inc. Enters Exclusive Distribution Agreement (date Fundz recorded it)
  • : SEC 8-K (8.01):
  • : SEC 8-K (7.01): On October 27, 2026, Microbot Medical Inc. announced via press release that ELMNT IR, a multisite outpatient interventional radiology practice in California, has signed an order to purchase a 12-month supply of the Company's LIBERTY Endovascular Robotic System devices. This marks ELMNT IR as the first Office-Based Laboratory customer globally to utilize these systems and the first customer for Microbot on the West Coast. The transaction signifies a key expansion in Microbot's customer base and operational presence in a strategic market. The details of this order and its potential impacts are further elaborated in the accompanying exhibit of the press release.
  • : SEC 8-K (7.01): On October 23, 2026, Microbot Medical Inc. announced that it will be attending the SIR EDGE 2026 conference scheduled from October 25-27, 2026 in Louisville, Kentucky. This disclosure is part of the Company's Regulation FD obligations, aiming to ensure that all investors have equal access to material information. The announcement may enhance the Company’s visibility and facilitate networking opportunities with industry peers and potential investors during the conference. The press release is included as Exhibit 99.1 to this Current Report on Form 8-K.
  • : SEC 8-K (7.01): On October 20, 2026, Microbot Medical Inc. announced via a press release the receipt of several new patent approvals in the U.S., Japan, China, and Canada. This reinforces the Company's global intellectual property portfolio, which now includes 44 issued patents and 49 pending applications, as it seeks to enhance the commercial adoption of its LIBERTY® System and pursue a CE Mark. These developments are aimed at positioning the Company for continued growth in key international markets. The announcement is linked to the Company's strategic efforts in expanding its technological footprint and market competitiveness.
  • : SEC 8-K (7.01): On October 6, 2026, Microbot Medical Inc. entered into a three-year exclusive Distribution Agreement with Medtechnica Ltd., a leading medical device distributor in Israel. This agreement allows Medtechnica to distribute the Company’s LIBERTY® Endovascular Robotic System throughout Israel, enhancing the Company's market presence in the region. The strategic partnership is expected to significantly contribute to the Company's growth in sales within the Israeli market, leveraging Medtechnica's established distribution channels. The announcement was made through a press release, signaling a positive impact on future operations and market reach.
  • : SEC 8-K (7.01): On September 25, 2026, Microbot Medical Inc. issued a press release to update certain growth strategies. The disclosure elaborates on the company's strategic direction and provides insights into upcoming initiatives intended to enhance their market presence and drive revenue growth. Although specific financials were not disclosed in the press release, the update reflects the company's response to market conditions and its commitment to innovation. This information is significant for investors assessing the future potential of Microbot Medical Inc.
  • : SEC 8-K (7.01): On August 11, 2026, Microbot Medical Inc. announced via a press release that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2026. The filing provides important highlights regarding the Company's performance during the second quarter. This disclosure is intended to inform investors about the Company's ongoing financial health and operations, although it explicitly states that the information should not be considered as filed under the Securities Exchange Act. The press release is included as Exhibit 99.1.
  • : SEC 8-K (5.02): On August 6, 2026, Microbot Medical Inc. executed Addendum #4 to the Employment Agreement with Rachel Vaknin, the Chief Financial Officer, to increase her annual base salary to NIS 864,000, equivalent to $288,000 at a presumed exchange rate of 3:1. This salary increase is effective from August 1, 2026. The Addendum details the modified financial terms but further specifics are available in Exhibit 10.1 attached to the filing. This adjustment is indicative of the company's commitment to retain key management talent in a competitive market.
  • : SEC 8-K (7.01): On July 21, 2026, Microbot Medical Inc. announced that CEO Harel Gadot will participate in the Society of Robotic Surgery annual meeting from July 23-26, 2026, in Fort Lauderdale, FL. He will present insights on the endovascular robotic market while discussing emerging technologies in vascular and cardiovascular sectors. This presentation highlights the company's engagement in advancing robotic surgery technologies and showcases their position in a growing market, which could influence future company strategies and investor interest.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Microbot Medical funding history

DateRoundAmount
Sep 2025Venture$25.2M
Feb 2025Venture$13.0M
Jan 2025Venture$8.6M
Jan 2025Venture$7.0M
Jun 2024Venture$1.8M

Leadership

  • Martin Madden, Director
  • Scott Burell, Director
  • Pratipatti Laxminarain, Director
  • Yoseph Bornstein, Director
  • Yoav Waizer, Director
  • Harel Gadot, Executive Officer, Director

Verified email and direct lines for Microbot Medical’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Microbot Medical files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Companies similar to Microbot Medical

About Microbot Medical: questions and answers

What does Microbot Medical do?

Microbot Medical’s vision is to improve the quality of life of millions of patients globally by advancing robotic technologies to perform surgical procedures within the human body, and offer physicians and their patients less invasive and more precise solutions. The company’s innovations tap into one of the fastest-growing spaces in the medical field, the minimal invasive space. Microbot Medical d

Where is Microbot Medical headquartered?

Microbot Medical is headquartered in Hingham, Massachusetts, United States.

How many employees does Microbot Medical have?

Microbot Medical has about 37 employees.

Has Microbot Medical raised funding?

Yes. Fundz has recorded 5 funding events for Microbot Medical. The most recent, $25.2M, was in Sep 2025.

What is the latest news on Microbot Medical?

On Oct 6, 2026, Microbot Medical Inc. Enters Exclusive Distribution Agreement

Is Microbot Medical a public company?

Yes. Microbot Medical is publicly traded under the ticker MBOT.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Microbot Medical across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.